Literature DB >> 24332763

Visit-to-visit variability in systolic blood pressure predicts development and progression of diabetic nephropathy, but not retinopathy, in patients with type 2 diabetes.

Toshiko Takao1, Yutaka Matsuyama2, Hiroyuki Yanagisawa3, Masatoshi Kikuchi4, Shoji Kawazu4.   

Abstract

OBJECTIVE: To investigate whether visit-to-visit variability in systolic blood pressure (SBP) can predict development and progression of diabetic nephropathy and retinopathy in patients with type 2 diabetes mellitus (T2DM).
METHODS: From 1995 through 1996, 664 T2DM patients visited our hospital for the first time and were subsequently examined 4 times or more and at least once annually. At first visit, 326 had normoalbuminuria, 644 had an estimated glomerular filtration rate (eGFR) of ≥ 45 ml/min/1.73 m(2), 526 had no diabetic retinopathy and 609 had no severe non-proliferative diabetic retinopathy (NPDR). They were followed through June 2012, at the latest.
RESULTS: Ninety patients developed microalbuminuria, 76 showed decrease of eGFR to <45 ml/min/1.73 m(2), 113 developed mild-moderate NPDR and 50 progression to severe NPDR. The unadjusted, age- and sex-adjusted and multivariate-adjusted hazard ratios for development and progression of nephropathy, but not retinopathy, increased across tertiles of the standard deviation (SD) of SBP. Both the SD and coefficient of variation (CV) of SBP were significant predictors of development and progression of nephropathy, but not retinopathy, independently of mean SBP.
CONCLUSION: Visit-to-visit SBP variability is an independent predictor of development and progression of diabetic nephropathy, but not retinopathy, in T2DM patients.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Blood pressure variability; Nephropathy; Retinopathy; Systolic blood pressure; Type 2 diabetes

Mesh:

Year:  2013        PMID: 24332763     DOI: 10.1016/j.jdiacomp.2013.11.003

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  7 in total

1.  Visit-to-visit systolic blood pressure variability and microvascular complications among patients with diabetes.

Authors:  Min-Woong Sohn; Noam Epstein; Elbert S Huang; Zhiping Huo; Nicholas Emanuele; George Stukenborg; Marylou Guihan; Junping Li; Elly Budiman-Mak
Journal:  J Diabetes Complications       Date:  2016-09-14       Impact factor: 2.852

Review 2.  Blood Pressure Variability and Autonomic Dysfunction.

Authors:  Vincenza Spallone
Journal:  Curr Diab Rep       Date:  2018-10-25       Impact factor: 4.810

3.  Psychosocial stress and changes in estimated glomerular filtration rate among adults with diabetes mellitus.

Authors:  Francis B Annor; Katherine E Masyn; Ike S Okosun; Douglas W Roblin; Michael Goodman
Journal:  Kidney Res Clin Pract       Date:  2015-08-19

4.  Prognostic importance of visit-to-visit blood pressure variability for micro- and macrovascular outcomes in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study.

Authors:  Claudia R L Cardoso; Nathalie C Leite; Gil F Salles
Journal:  Cardiovasc Diabetol       Date:  2020-05-02       Impact factor: 9.951

5.  The Impact of Systolic Blood Pressure, Pulse Pressure, and Their Variability on Diabetes Retinopathy among Patients with Type 2 Diabetes.

Authors:  Qingqing Lou; Xue Chen; Kun Wang; Huanhuan Liu; Zongjun Zhang; Yaujiunn Lee
Journal:  J Diabetes Res       Date:  2022-03-22       Impact factor: 4.011

6.  Discordance in risk factors for the progression of diabetic retinopathy and diabetic nephropathy in patients with type 2 diabetes mellitus.

Authors:  Ki-Ho Song; Jee-Sun Jeong; Mee Kyoung Kim; Hyuk-Sang Kwon; Ki-Hyun Baek; Seung-Hyun Ko; Yu-Bae Ahn
Journal:  J Diabetes Investig       Date:  2018-11-07       Impact factor: 4.232

7.  Visit-to-visit variability of glycemia and vascular complications: the Hoorn Diabetes Care System cohort.

Authors:  Roderick C Slieker; Amber A W H van der Heijden; Giel Nijpels; Petra J M Elders; Leen M 't Hart; Joline W J Beulens
Journal:  Cardiovasc Diabetol       Date:  2019-12-12       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.